Skip to main content

Advertisement

Log in

Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy

  • Neurophthalmology
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Objective

To investigate systematically the role of systemic corticosteroid therapy in non-arteritic anterior ischemic optic neuropathy (NA-AION).

Methods

The study consists of a cohort of 613 consecutive patients (696 eyes), first seen in our clinic from 1973 to 2000. Of this cohort, 312 patients (364 eyes) voluntarily opted for systemic steroid therapy, and 301 (332 eyes) for no treatment. At first visit, all patients in both groups had a detailed ophthalmic and medical history, and comprehensive ophthalmic evaluation. Visual evaluation was done by recording Snellen visual acuity, and visual fields with a Goldmann perimeter. The same ophthalmic evaluation was performed at each follow-up visit. Patients in the steroid-treated group were initially given 80 mg Prednisone daily for 2 weeks, and then tapered down to 70 mg for 5 days, 60 mg for 5 days, and then cutting down by 5 mg every 5 days. Visual outcome in the two groups was compared

Results

Median follow-up was 3.8 years. At 6 months from onset of NA-AION, of the eyes with initial visual acuity 20/70 or worse and seen within 2 weeks of onset, there was visual acuity improvement in 69.8% (95% confidence interval (CI): 57.3%, 79.9%) in the treated group, compared to 40.5% (95% CI: 29.2%, 52.9%) in the untreated group (odds ratio of improvement: 3.39; 95% CI:1.62, 7.11; p = 0.001). Comparison of visual field defect at 6 months from onset of NA-AION, among those seen within 2 weeks of NA-AION onset with moderate to severe initial visual field defect, there was improvement in 40.1% (95% CI: 33.1%, 47.5%) of the treated group, and 24.5% (95% CI: 17.7%, 32.9%) of the untreated group (odds ratio: 2.06, 95% CI: 1.24, 3.40; p = 0.005). In both treated and untreated groups, the visual acuity and visual fields kept improving up to about 6 months from onset of NA-AION, and very little thereafter.

Conclusion

This study suggested that NA-AION eyes treated during the acute phase with systemic corticosteroids resulted in a significantly higher probability of improvement in visual acuity (p = 0.001) and visual field (p = 0.005) than in the untreated group. Both visual acuity and visual fields improved up to 6 months after onset of NA-AION.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Beck RW, Hayreh SS, Podhajsky PA, Tan E-S, Moke PS (1997) Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 123:212–217

    PubMed  CAS  Google Scholar 

  2. Beck RW, Servais GE, Hayreh SS (1987) Anterior ischemic optic neuropathy IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 94:1503–1508

    PubMed  CAS  Google Scholar 

  3. Beri M, Klugman MR, Kohler JA, Hayreh SS (1987) Anterior ischemic optic neuropathy VII. Incidence of bilaterality and various influencing factors. Ophthalmology 94:1020–1028

    PubMed  CAS  Google Scholar 

  4. Dai J, Buijs R, Swaab D (2004) Glucocorticoid hormone (cortisol) affects axonal transport in human cortex neurons but shows resistance in Alzheimer’s disease. Br J Pharmacol 143:606–610

    Article  PubMed  CAS  Google Scholar 

  5. Esterman B (1968) Grid for scoring visual fields. II. Perimeter. Arch Ophthalmol 79:400–406

    PubMed  CAS  Google Scholar 

  6. Foulds WS (1969) Visual disturbances in systemic disorders: optic neuropathy and systemic disease. Trans Ophthalmol Soc UK 89:125–146

    Google Scholar 

  7. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E (2002) Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86:247–248

    Article  PubMed  Google Scholar 

  8. Hayreh SS (1969) Blood supply of the optic nerve head and its role in optic atrophy, glaucoma and oedema of the optic disc. Br J Ophthalmol 53:721–748

    Article  PubMed  CAS  Google Scholar 

  9. Hayreh SS (1972) Optic disc vasculitis. Br J Ophthalmol 56:652–670

    Article  PubMed  CAS  Google Scholar 

  10. Hayreh SS (1974) Pathogenesis of cupping of the optic disc. Br J Ophthalmol 58:863–876

    Article  PubMed  CAS  Google Scholar 

  11. Hayreh SS (1974) Anterior ischaemic optic neuropathy III. Treatment, prophylaxis, and differential diagnosis. Br J Ophthalmol 58:98l–989

    Google Scholar 

  12. Hayreh SS (1977) Optic disc edema in raised intracranial pressure V. Pathogenesis. Arch Ophthalmol 95:1553–1565

    PubMed  CAS  Google Scholar 

  13. Hayreh SS (1978) Fluids in the anterior part of the optic nerve in health and disease. Surv Ophthalmol 23:1–25

    Article  PubMed  CAS  Google Scholar 

  14. Hayreh SS (1990) Anterior ischaemic optic neuropathy: Differentiation of arteritic from non-arteritic type and its management. Eye 4:25–41

    PubMed  Google Scholar 

  15. Hayreh SS (2001) The blood supply of the optic nerve head and the evaluation of it - Myth and reality. Prog Retin Eye Res 20:563–593

    Article  PubMed  CAS  Google Scholar 

  16. Hayreh SS (2003) Management of central retinal vein occlusion. Ophthalmologica 217:167–188

    Article  PubMed  Google Scholar 

  17. Hayreh SS (2004) Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye 18:1188–1206

    Article  PubMed  CAS  Google Scholar 

  18. Hayreh SS (2005) Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 24:493–519

    Article  PubMed  Google Scholar 

  19. Hayreh SS (2008) Intravitreal triamcinolone for non-arteritic anterior ischemic optic neuropathy. J Neuroophthalmol 28:77–78

    Google Scholar 

  20. Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES (1990) Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion: a 10-year prospective study. Graefes Arch Clin Exp Ophthalmol 228:281–296

    Article  PubMed  CAS  Google Scholar 

  21. Hayreh SS, Massanari RM, Yamada T, Hayreh SMS (1981) Experimental allergic encephalomyelitis I. Optic nerve and central nervous system manifestations.. Invest Ophthalmol Vis Sci 21:256–269

    PubMed  CAS  Google Scholar 

  22. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B (1997) Giant cell arteritis: Validity and reliability of various diagnostic criteria. Am J Ophthalmol 123:285–296

    PubMed  CAS  Google Scholar 

  23. Hayreh SS, Podhajsky PA, Zimmerman B (1997) Non-arteritic anterior ischemic optic neuropathy - Time of onset of visual loss. Am J Ophthalmol 124:641–647

    PubMed  CAS  Google Scholar 

  24. Hayreh SS, Podhajsky PA, Zimmerman B (1999) Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica 213:76–96

    Article  PubMed  CAS  Google Scholar 

  25. Hayreh SS, Zimmerman B (2003) Management of giant cell arteritis. Ophthalmologica 217:239–259

    Article  PubMed  Google Scholar 

  26. Hayreh SS, Zimmerman B (2005) Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: Their pattern and prevalence at the initial presentation. Arch Ophthalmol 123:1554–1562

    Article  PubMed  Google Scholar 

  27. Hayreh SS, Zimmerman MB (2007) Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 245:1107–1121

    Article  PubMed  Google Scholar 

  28. Hayreh SS, Zimmerman B (2008) Non-arteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology 115:298–305

    Article  PubMed  Google Scholar 

  29. Hayreh SS, Zimmerman B, Kardon RH (2002) Visual improvement with corticosteroid therapy in giant cell arteritis: Report of a large study and review of literature. Acta Ophthalmol Scand 80:355–367

    Article  PubMed  Google Scholar 

  30. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL (1994) Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 117:603–624

    PubMed  CAS  Google Scholar 

  31. Ischemic Optic Neuropathy Decompression Trial Research Group (2000) Ischemic optic neuropathy decompression trial: twenty-four-month update. Arch Ophthalmol 118:793–798

    Google Scholar 

  32. Jonas JB, Kreissig I, Degenring RF (2002) Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240:782–783

    Article  PubMed  Google Scholar 

  33. Jonas JB, Söfker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132:425–427

    Article  PubMed  CAS  Google Scholar 

  34. Jonas JB, Spandau UH, Harder B, Saunder G (2007) Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 245:749–750

    Article  PubMed  CAS  Google Scholar 

  35. Kaderli B, Avci R, Yucel A, Guler K, Gelisken O (2007) Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 27:164–168

    PubMed  Google Scholar 

  36. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927

    Article  PubMed  Google Scholar 

  37. McLeod D, Marshall J, Kohner EM (1980) Role of axoplasmic transport in the pathophysiology of ischaemic disc swelling. Br J Ophthalmol 64:247–261

    Article  PubMed  CAS  Google Scholar 

  38. Miller GR, Smith JL (1966) Ischemic optic neuropathy. Am J Ophthalmol 62:103–115

    PubMed  CAS  Google Scholar 

  39. Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, Dickersin K Ischemic Optic Neuropathy Decompression Trial Research Group (2002) The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 134:317–328

    Article  PubMed  Google Scholar 

  40. The Ischemic Optic Neuropathy Decompression Trial Research Group (1995) Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 273:625–632

    Article  Google Scholar 

Download references

Acknowledgements

We are extremely grateful to Drs. Randy H. Kardon, H. Stanley Thompson and Michael Wall, and Mrs. Patricia Podhajsky for their invaluable help with the visual field evaluation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sohan Singh Hayreh.

Additional information

Supported by grant EY-1151 from the National Institutes of Health, Bethesda, Maryland, and in part by unrestricted grant from Research to Prevent Blindness, Inc., New York.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayreh, S.S., Zimmerman, M.B. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246, 1029–1046 (2008). https://doi.org/10.1007/s00417-008-0805-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0805-8

Keywords

Navigation